Bifidobacterium longum and IBS

What 2 graded rows on bifidobacterium longum agree on for IBS, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Bifidobacterium longum page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Bifidobacterium longum page, with its PubMed record.

Supplement

Bifidobacterium longum Choose another

2 rows · 664 people

Split. 1 row found an improvement and 1 had mixed results.

Mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade C, is a randomized trial of 362 people (2006) and found an improvement.

The rows run from 302 to 362 people, published from 2006 to 2017: 2 single studies.

1 improved · 1 mixed

Grade CIBS symptoms (abdominal pain, bloating, bowel habit) · Improved
RCT · n 362 · 2006 · Women with IBS of any subtype in UK primary care
1 million, 100 million or 10 billion CFU/day vs placebo · 4 weeks
100 million CFU was superior to placebo and to the other doses for abdominal pain, composite score, bloating, bowel dysfunction, incomplete evacuation, straining and gas; global relief exceeded placebo by more than 20% (p < 0.02). The 1 million and 10 billion CFU doses did not differ from placebo; the 10 billion CFU capsule had formulation problems.
Row on the Bifidobacterium longum page · PubMed 16863564 (opens PubMed)
Grade CAbdominal discomfort and bloating in people not under a doctor's care · Mixed
RCT · n 302 · 2017 · US adults with abdominal discomfort and bloating at least twice a week for 3 months (275 evaluable)
1 billion CFU/day · 4 weeks
Symptom severity improved in both groups with no difference between probiotic and placebo (P > 0.3); the probiotic group had more bloating-free days (P < 0.05).
Row on the Bifidobacterium longum page · PubMed 27845337 (opens PubMed)